HK1068278A1 - Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant - Google Patents

Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant

Info

Publication number
HK1068278A1
HK1068278A1 HK05100590A HK05100590A HK1068278A1 HK 1068278 A1 HK1068278 A1 HK 1068278A1 HK 05100590 A HK05100590 A HK 05100590A HK 05100590 A HK05100590 A HK 05100590A HK 1068278 A1 HK1068278 A1 HK 1068278A1
Authority
HK
Hong Kong
Prior art keywords
antioxidant
pharmaceutical composition
polyethylene glycol
active compound
aminosulfonyl group
Prior art date
Application number
HK05100590A
Other languages
English (en)
Inventor
Ping Gao
Tiehua Huang
Russell H Robins
Juliane M Bauer
Jane E Guido
Andrew M Brugger
Aziz Karim
Fred Hassan
James C Forbes
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1068278(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of HK1068278A1 publication Critical patent/HK1068278A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05100590A 2001-04-17 2005-01-21 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant HK1068278A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28458901P 2001-04-17 2001-04-17
US35795902P 2002-02-19 2002-02-19
PCT/US2002/011690 WO2002102376A1 (en) 2001-04-17 2002-04-12 ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE COMPOUND HAVING AN AMINOSULFONYL GROUP (cox-2 INHIBITOR), A POLYETHYLENE GLYCOL AND A FREE-RADICAL SCAVENGING ANTIOXIDANT

Publications (1)

Publication Number Publication Date
HK1068278A1 true HK1068278A1 (en) 2005-04-29

Family

ID=26962690

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100590A HK1068278A1 (en) 2001-04-17 2005-01-21 Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant

Country Status (22)

Country Link
US (5) US20030105144A1 (ru)
EP (2) EP1494666A1 (ru)
JP (2) JP2004529986A (ru)
KR (1) KR20040012761A (ru)
CN (1) CN1292746C (ru)
AR (1) AR033466A1 (ru)
AT (1) ATE370938T1 (ru)
AU (1) AU2002254609B2 (ru)
BR (1) BR0208947A (ru)
CA (2) CA2444356A1 (ru)
CZ (1) CZ20032793A3 (ru)
DE (1) DE60221977T2 (ru)
EA (1) EA006677B1 (ru)
ES (1) ES2289139T3 (ru)
HK (1) HK1068278A1 (ru)
IL (1) IL158200A0 (ru)
MX (1) MXPA03009410A (ru)
NO (1) NO20034627L (ru)
NZ (1) NZ528716A (ru)
PE (1) PE20021108A1 (ru)
PL (1) PL367180A1 (ru)
WO (2) WO2002102376A1 (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
US6849613B2 (en) 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
CA2488526A1 (en) * 2002-06-26 2004-01-08 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
AU2003247622A1 (en) * 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
EP1627644A4 (en) * 2003-05-23 2012-01-18 Hisamitsu Pharmaceutical Co PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION WITH AN NON-TEROIDAL INFLAMMATORY MEDICAMENT AND AN INTERLEUKIN 1A PRODUCTION INHIBITOR
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
EA200601648A1 (ru) 2004-04-07 2007-04-27 Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EP1778292A2 (en) * 2004-08-12 2007-05-02 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US20090048667A1 (en) * 2005-11-16 2009-02-19 Tokai University Educational System Controlled Drug-Release Composition and Drug-Releasable Medical Device
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
MX2008014450A (es) * 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
US20080229477A1 (en) * 2007-03-22 2008-09-25 Mcgough Charles B Football glove for quarterbacks
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
SG10201500152UA (en) * 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
CN102000018B (zh) * 2010-02-09 2012-07-04 浙江大学宁波理工学院 一种含塞来昔布的固体分散物及其制备方法和应用
EP2611442B1 (en) * 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
RU2617988C2 (ru) * 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
EP2670397B1 (en) * 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
JP5973204B2 (ja) * 2011-03-30 2016-08-23 興和株式会社 カフェイン含有液状組成物及び該組成物を充填したカプセル剤
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CN103127520B (zh) * 2011-12-01 2016-05-04 天津键凯科技有限公司 聚乙二醇与坦索罗辛的结合物及其药物组合物
CN103372216B (zh) * 2012-04-26 2015-05-06 北京京卫燕康药物研究所有限公司 一种含有塞来昔布的固体药物组合物
JP6088760B2 (ja) * 2012-07-10 2017-03-01 三菱瓦斯化学株式会社 過酸化水素の製造方法
WO2014012000A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US10987365B2 (en) * 2012-10-01 2021-04-27 Gm Pharmaceuticals, Inc. Compositions and methods for the treatment of pain
US20160158410A1 (en) * 2013-07-22 2016-06-09 Albert-Ludwigs-Universität Freiburg Polysaccharide hydrogels for injection with tunable properties
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
CN104892514A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种咪唑类新化合物
WO2016196085A1 (en) * 2015-05-29 2016-12-08 Kiel Laboratories, Inc. Liquid formulations of celecoxib for oral administration
PL3377041T3 (pl) * 2015-11-16 2024-03-11 Medincell S.A. Sposób morselizacji i/lub kierowania farmaceutycznie aktywnych składników do tkanki maziowej
CN111848538A (zh) * 2019-04-25 2020-10-30 山东墨海生物科技有限公司 一种帕瑞昔布钠杂质的合成方法
CN112409283A (zh) * 2020-11-24 2021-02-26 苏州璞正医药有限公司 一种帕瑞昔布衍生物及其制备方法和应用
WO2023209722A1 (en) * 2022-04-28 2023-11-02 Rambam Med-Tech Ltd. Composition for use in the treatment of a disease
CN115453011A (zh) * 2022-10-19 2022-12-09 天和药业股份有限公司 一种地拉考昔含量检测方法

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644449A (en) 1969-03-27 1972-02-22 Texaco Inc Bis(perfluoroalkyl) nitroxide mercuride
US4146721A (en) 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3901908A (en) 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
US3984431A (en) 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2248027B2 (ru) 1973-10-18 1977-09-09 Serdex
US4302461A (en) 1979-08-09 1981-11-24 E. I. Du Pont De Nemours And Company Antiinflammatory 5-substituted-2,3-diarylthiophenes
CA1128526A (en) 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US4372964A (en) 1980-10-30 1983-02-08 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols
US4381311A (en) 1980-12-29 1983-04-26 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-(polyhalomethyl)-2-thiophenemethanols
US4427693A (en) 1981-08-05 1984-01-24 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines
US4590205A (en) 1982-03-03 1986-05-20 E. I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
US4820827A (en) 1982-03-03 1989-04-11 E. I. Du Pont De Nemours And Company 2,3-diaryl-5-bromothiophene compounds of use for the treatment of inflammaton and dysmenorrhea
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
ZA826501B (en) 1982-09-06 1984-04-25 Du Pont Anti-hypertensive imidazole derivative
US4533666A (en) 1983-06-22 1985-08-06 Eli Lilly And Company 6-Phenyl-2,3-bis-(4-methoxyphenyl)-pyridine derivatives having anti-inflammatory activity
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4632930A (en) 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4805354A (en) * 1986-05-07 1989-02-21 General Electric Company Apparatus and method for lapping an edge surface of an object
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0272704A3 (en) 1986-12-26 1990-11-22 Sanwa Kagaku Kenkyusho Co., Ltd. Use of pyrazole derivatives in the treatment of immunity diseases and nephropathy
US5051518A (en) 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
JP2590124B2 (ja) 1987-08-12 1997-03-12 国際試薬株式会社 水溶性テトラゾリウム化合物およびその化合物を用いる還元性物質の測定方法
CA2003283A1 (en) 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH04134077A (ja) 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
JPH04277724A (ja) 1991-03-06 1992-10-02 Sumitomo Electric Ind Ltd 有機非線形光学材料
DE69132293D1 (de) 1991-03-07 2000-08-10 Hisamitsu Pharmaceutical Co Diphenylthiazolderivate mit antiinflammatorischer aktivität
WO1992019604A1 (fr) 1991-05-01 1992-11-12 Taiho Pharmaceutical Co., Ltd. Nouveau derive d'isoxazole et sel de ce derive
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
WO1993014082A1 (en) 1992-01-13 1993-07-22 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH05323522A (ja) 1992-05-20 1993-12-07 Fuji Photo Film Co Ltd 黒白ハロゲン化銀写真感光材料の処理方法
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en) 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1115576A (zh) 1993-10-15 1996-01-24 盐野义制药株式会社 具有细胞浆磷脂酶a2抑制活性的噁唑啉酮衍生物
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PL326700A1 (en) 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
DE69737605T2 (de) 1996-01-23 2008-04-03 Shionogi & Co., Ltd. Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
ES2125161B1 (es) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S Nuevos derivados de 2-(3h)-oxazolona.
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
ES2311571T3 (es) 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP0919228A4 (en) * 1996-08-02 2001-12-12 Hisamitsu Pharmaceutical Co CAPSULES FOR ORAL PREPARATIONS AND CAPSULE PREPARATIONS FOR ORAL ADMINISTRATION
CA2263886A1 (en) 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
US5770215A (en) * 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
ES2131015B1 (es) 1997-09-12 2000-03-01 Almirall Prodesfarma Sa Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas.
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
WO1999023150A1 (en) 1997-11-03 1999-05-14 Medlogic Global Corporation Cyanoacrylate polymer compositions comprising an antimicrobial agent
AU718356B2 (en) * 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
AU3993899A (en) * 1998-05-18 1999-12-06 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
ES2137138B1 (es) 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
BR9915011A (pt) 1998-11-03 2001-08-07 Glaxo Group Ltd Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
PL349216A1 (en) 1998-12-23 2002-07-01 Searle & Co Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
EP1109799B1 (en) 1999-04-14 2003-12-17 Pacific Corporation 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
AU765203B2 (en) 1999-04-19 2003-09-11 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
AU5873000A (en) 1999-06-24 2001-01-31 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors forthe treatment of inflammation
WO2001016138A1 (en) 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
EP1212051A4 (en) 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
AR025867A1 (es) * 1999-09-27 2002-12-18 American Home Prod Formulacion portasdora farmaceutica
CZ20021083A3 (cs) * 1999-09-27 2002-06-12 American Cyanamid Company Farmaceutický prostředek
AU7615200A (en) * 1999-09-27 2001-04-30 American Cyanamid Company Vasopressin agonist formulation and process
US6323226B1 (en) 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
GB9930075D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
EP1274425A1 (en) * 2000-04-18 2003-01-15 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor
CA2406685C (en) 2000-04-21 2006-10-31 Shionogi & Co., Ltd. Oxadiazole derivatives having anticancer effects
AU2001248765A1 (en) 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
AU2001248820A1 (en) 2000-04-28 2001-11-12 Shionogi And Co., Ltd. Thiazole and oxazole derivatives
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6949571B2 (en) 2000-06-12 2005-09-27 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2001282990A1 (en) 2000-07-27 2002-02-13 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
IN191090B (ru) 2000-08-29 2003-09-20 Ranbanx Lab Ltd

Also Published As

Publication number Publication date
JP2004529986A (ja) 2004-09-30
MXPA03009410A (es) 2004-01-29
ES2289139T3 (es) 2008-02-01
ATE370938T1 (de) 2007-09-15
AR033466A1 (es) 2003-12-17
CA2444356A1 (en) 2002-12-27
WO2002102376A1 (en) 2002-12-27
CZ20032793A3 (cs) 2004-11-10
EP1494666A1 (en) 2005-01-12
NO20034627D0 (no) 2003-10-16
US20040002522A1 (en) 2004-01-01
WO2002102376A8 (en) 2003-04-24
EA200301018A1 (ru) 2004-06-24
KR20040012761A (ko) 2004-02-11
EP1379513B1 (en) 2007-08-22
US20050032852A1 (en) 2005-02-10
US20030055012A1 (en) 2003-03-20
US6809111B2 (en) 2004-10-26
NO20034627L (no) 2003-12-12
DE60221977D1 (de) 2007-10-04
PE20021108A1 (es) 2003-01-16
PL367180A1 (en) 2005-02-21
AU2002254609B2 (en) 2007-06-21
DE60221977T2 (de) 2008-05-15
WO2002083655A1 (en) 2002-10-24
EA006677B1 (ru) 2006-02-24
EP1379513A1 (en) 2004-01-14
US20030105144A1 (en) 2003-06-05
CN1516581A (zh) 2004-07-28
BR0208947A (pt) 2004-10-19
CA2444267A1 (en) 2002-10-24
US6613790B2 (en) 2003-09-02
IL158200A0 (en) 2004-05-12
JP2004526765A (ja) 2004-09-02
US20050112197A1 (en) 2005-05-26
CN1292746C (zh) 2007-01-03
NZ528716A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
HK1068278A1 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL175953A (en) Derivatives of 3-Cycloalkylaminopyrrolidine, their Pharmaceutical Salts and Preparations Containing Them
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
MXPA03006775A (es) Formulacion farmaceutica.
MXPA03007215A (es) Formulaciones farmaceuticas.
AU2002341205A1 (en) Pharmaceutical compositions comprising cyclosporin
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
CA2347195A1 (en) Oral pharmaceutical compositions containing buprenorphin
AU2002340573A1 (en) Powdery active ingredient formulations
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
GB0107751D0 (en) Pharmaceutically active compounds
GB0105893D0 (en) Pharmaceutically active compounds
AU2002350386A1 (en) Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
GB0106631D0 (en) Pharmaceutically active compounds
AUPR277401A0 (en) Physiologically active bracing
AU2001248943A1 (en) Pharmaceutical curative compound
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2003244259A1 (en) Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient
AU4884701A (en) Malonanilic acid derivatives, medicinal compositions containing the same and usethereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110412